Advertisement
Canada markets open in 6 hours 32 minutes

  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CAD/USD

    0.7313
    -0.0007 (-0.10%)
     

  • CRUDE OIL

    83.64
    +0.28 (+0.34%)
     

  • Bitcoin CAD

    91,303.56
    +526.79 (+0.58%)
     

  • CMC Crypto 200

    1,416.89
    -7.21 (-0.51%)
     

  • GOLD FUTURES

    2,339.10
    -3.00 (-0.13%)
     

  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • NASDAQ futures

    17,727.00
    +120.25 (+0.68%)
     

  • VOLATILITY

    15.69
    -1.25 (-7.38%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6836
    0.0000 (0.00%)
     

Avid Bioservices to Participate in the Credit Suisse 31st Annual Healthcare Conference

Avid Bioservices, Inc
·1 min read
Avid Bioservices, Inc
Avid Bioservices, Inc

TUSTIN, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the Credit Suisse 31st Annual Healthcare Conference. Nick Green, president and chief executive officer of Avid Bioservices, will deliver a corporate presentation at the conference, which will take place November 7-10, 2022, in Rancho Palos Verdes, CA.

Details of the company’s participation are as follows:

  • Credit Suisse 31st Annual Healthcare Conference
    Conference Date: November 7-10, 2022
    Presentation Time/Date: 12:50 - 1:20 p.m. Pacific on Wednesday, November 9, 2022
    Location: Terranea Resort, Rancho Palos Verdes, CA

ADVERTISEMENT

About Avid Bioservices, Inc.

Avid Bioservices (NASDAQ:CDMO), an S&P SmallCap 600 company, is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 29 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com

CONTACT: Contacts: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 sdiaz@vidasp.com Tim Brons (Media) Vida Strategic Partners 415-675-7402 tbrons@vidasp.com